Maintenance of Efficacy.

Status:
Withdrawn

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

The hypothesis of Study A6061054 is to demonstrate superiority of efficacy of esreboxetine at 3 and 6 months compared to placebo.

Phase 3

Pfizer